pharmaphorum

SEPTEMBER 22, 2022

The company said this morning that US sales growth is its main priority, and that it will be led in the near-term by “high-value” new drugs Kisqali (ribociclib), iptacopan, Pluvicto (lutetium Lu 177 vipivotide tetraxetan), remibrutinib, and Scemblix (asciminib). billion by 2024.

Management 52

Management Sales Patients Marketing 52

pharmaphorum

JULY 26, 2022

It had expected the drug would not face biosimilar competition in Europe until at least 2027. Biogen has been attempting to defend its franchise with a subcutaneous formulation given once a month, which was approved in the EU and UK last year but hasn’t yet made it past the FDA in the US.

Competition 52

Competition Side effects Marketing Sales 52

pharmaphorum

JANUARY 9, 2023

Albireo secured approval in the US and Europe for the ileal bile acid transport inhibitor (IBATi) drug in 2021 for the treatment of pruritus (itching) in patients with rare disorder progressive familial intrahepatic cholestasis (PFIC), and has said sales should reach $24 million this year. billion deal.

Transportation 52

Transportation Sales Leads FDA 52

pharmaphorum

JULY 18, 2022

Tysabri made worldwide sales of just under $2.1 It had expected the drug would not face biosimilar competition in Europe until at least 2027. billion last year, split roughly half and half between the US and the rest of the world, and is Biogen’s biggest seller. Europe accounted for an estimated $850 million of the total.

Competition 52

Competition Marketing Sales Medicine 52

pharmaphorum

JANUARY 10, 2023

New drugs for immunological and inflammatory diseases feature prominently among new product launches this year that could top $1 billion in annual sales by 2027 or be clinical “game changers,” according to Clarivate.

FDA 52

FDA Marketing Pharma Sales 52

Clarivate

AUGUST 27, 2024

Since the FDA’s approval of the first pulsed field ablation (PFA) system in the U.S. and ramped up sales of PFA systems in Europe. FDA approval in January 2024. FDA approval in the fourth quarter, with Johnson & Johnson’s Varipulse system close behind, so competition will pick up. Boston Scientific Corp. s Farapulse.

Marketing 52

Marketing FDA Competition Medical 52

European Pharmaceutical Review

FEBRUARY 22, 2023

Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. Top companies and drugs by sales in 2021. 2 Most biotherapeutics are delivered parenterally, with some exceptions being ocular or inhaled formulations. References Urquhart L. Nature Reviews Drug Discovery.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Safety Pharmaceutical 105

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. Anti-obesity therapeutic landscape. million in Q3.

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. Anti-obesity therapeutic landscape. million in Q3.

Medical 98

Medical Manufacturing Insurance Side effects 98

Legacy MEDSearch

MAY 23, 2022

BN by 2027. Lazurite’s ArthroFree System is the first wireless surgical camera system to receive FDA market clearance for arthroscopy and general endoscopy. This system has helped propel the arthroscopic market to an expected US $16.3 The Cleveland-based company (est.

Food and Drug Administration 52

Food and Drug Administration Medicine Recruitment Physicians 52

Legacy MEDSearch

JULY 24, 2023

Trial results are expected in 2027. Magnus’ first FDA-cleared product is the Magnus Neuromodulation System with SAINT Technology, which received FDA Breakthrough Device Designation for its novel, rapid-acting therapy for treatment-resistant depression. About Magnus Magnus Medical, Inc. ,

Medical 52

Medical Recruitment FDA Patients 52

Pharmaceutical Technology

JANUARY 10, 2023

billion in sales in 2019, increasing to $136.2 billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. Mounjaro is forecast to compete for significant market share with semaglutide and also Lilly’s Trulicity (dulaglutide), reaching peak sales of $10.2

Marketing 52

Marketing Physicians Sales Leads 52

Pharmaceutical Technology

APRIL 24, 2023

Covid-19 vaccines from Moderna and Pfizer /BioNTech, which use lipid nanoparticles, became the only two FDA-approved vaccines for almost all ages. However, after a period of slow movement in the field, the FDA approved the first nanodrug, Doxil, for Kaposi sarcoma in 1995. GlobalData is the parent company of Pharmaceutical Technology.

Pharmaceutical 59

Pharmaceutical Medicine Sales FDA 59

Pharmaceutical Technology

SEPTEMBER 23, 2022

It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. Viatris is seeking approval from the US Food and Drug Administration (FDA) to market Januvia and Janumet’s generic versions in the country. Merck has also permitted the sale of generic versions of Janumet XR to the market in July 2026 or before.

Food and Drug Administration 69

Food and Drug Administration FDA Food Marketing 69